logo color s and clearside.jpg
Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
December 09, 2016 09:20 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
December 07, 2016 16:02 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema
November 15, 2016 08:23 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Announces Third Quarter 2016 Financial Results and Provides Corporate Update
November 09, 2016 07:00 ET | Clearside Biomedical, Inc.
Phase 3 Program of Zuprata™ for Macular Edema Associated with Retinal Vein Occlusion to be Initiated in the First Half of 2017 Phase 1/2 Trial for Diabetic Macular Edema to be Initiated by the End...
logo color s and clearside.jpg
Clearside Biomedical, Inc. to Present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016
November 08, 2016 16:30 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Names Rick McElheny as Vice President, Business Development
November 08, 2016 07:00 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
October 10, 2016 07:00 ET | Clearside Biomedical, Inc.
Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis ...
logo color s and clearside.jpg
Clearside Biomedical, Inc. to Present at the 2016 Ladenburg Thalmann Healthcare Conference
September 20, 2016 16:30 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Reports Second Quarter 2016 Financial Results
August 11, 2016 07:00 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 10, 2016 07:00 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat...